1051:
Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E (2002). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian
Prostatic
521:
Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO (July 1998). "Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate
309:
Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A (November 2019). "Randomised Trial of
Adjuvant
1095:
Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J (2008). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the
857:
Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL (December 2014). "Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the
1015:
Hedlund PO, Henriksson P (March 2000). "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The
Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study".
821:
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (January 2013). "Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects".
493:
Aro J, Ruutu M, Juusela H, Hansson E, Permi J (1993). "Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The
Finnprostate Group".
600:
Mikkola A, Aro J, Rannikko S, Ruutu M (March 2007). "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy".
386:
Haapiainen R, Rannikko S, Alfthan O (October 1986). "Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study".
944:
Lukkarinen O, Kontturi M (June 1994). "Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study".
422:
Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS (May 1989). "High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group".
785:
Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (June 2012). "The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer".
279:
Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Aro J, Ervasti J, Hansson E, Hurme K, Juusela H, Mäkinen J (1985). "Early results of the
Finnish Multicentre Study of Prostatic Cancer (Finnprostate)".
557:
Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M (2005). "Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate".
458:
Haapiainen R, Rannikko S, Alfthan O (July 1990). "Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group".
646:"A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer"
1160:
210:
901:
Aro J (1991). "Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population".
310:
Radiotherapy
Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension".
693:
Mikkola A, Aro J, Rannikko S, Ruutu M (2009). "Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors".
738:"Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group"
1145:
754:
737:
205:
1150:
980:
Bishop MC, Lemberger RJ, Selby C, Lawrence WT (September 1989). "Oestrogen dosage in prostatic cancer: the threshold effect?".
240:
253:
242:
Parenteral
Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response (CRD Report 33)
150:
176:
group also assessed polyestradiol phosphate 160 mg/month versus orchiectomy for advanced prostate cancer. The
127:
239:
Emmans Dean M, Norman G, Hodges Z, Ritchie G, Light K, Eastwood A, Langley R, Sydes M, Parmar M, Abel P (2006),
1155:
154:
144:
123:
98:
80:
181:
136:
107:
86:
72:
365:"Comparison of primary orchiectomy and estrogen therapy in advanced prostatic cancer - a 2 years follow-up"
168:
A related study, by the
Finnish Zoladex Multicentre Study Group, assessed polyestradiol phosphate versus
40:
115:
1121:
1077:
926:
883:
767:
718:
675:
626:
582:
364:
345:
1113:
1069:
1033:
997:
962:
918:
875:
839:
803:
759:
710:
667:
618:
574:
539:
503:
475:
440:
404:
337:
288:
249:
1105:
1061:
1025:
989:
954:
910:
867:
831:
795:
749:
702:
657:
610:
566:
531:
467:
432:
396:
327:
319:
68:
248:, York: Centre for Reviews and Dissemination/University of York/York Publishing Services,
52:
55:. The first publication by the group was in 1985 and the latest publication was in 2019.
993:
471:
436:
400:
173:
48:
1029:
1139:
662:
645:
535:
349:
1125:
930:
887:
771:
722:
630:
586:
1081:
679:
259:
119:
871:
835:
323:
67:
FinnProstate-1 (FinnProstate-I; Finnish
Multicentre Study of Prostatic Cancer) –
189:
185:
140:
94:
76:
1065:
799:
1109:
958:
706:
570:
914:
193:
169:
111:
17:
1117:
1073:
1037:
879:
843:
807:
763:
755:
10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e
714:
671:
622:
578:
341:
1001:
966:
922:
543:
507:
479:
444:
408:
292:
332:
614:
90:
63:
The studies conducted by the FinnProstate group include the following:
44:
177:
149:
FinnProstate-7 (FinnProstate-VII) – intermittent versus continuous
1096:
Scandinavian
Prostatic Cancer Group (SPCG) Study No. 5".
644:
Mikkola AK, Aro JL, Rannikko AS, Ruutu ML (May 2008).
234:
232:
230:
228:
226:
75:
80 mg/month (160 mg/month initially) versus
736:
Mikkola AK, Aro JL, Rannikko SA, Salo JO (May 1999).
184:
240 mg/month versus combined androgen blockade (
139:
240 month (320 mg/month initially) versus
363:Haapiainen R, Rannikko S, Alfthan O (April 1986).
211:Prostate Adenocarcinoma: TransCutaneous Hormones
71:150 μg/day (1 mg/day initially) plus
304:
302:
274:
272:
103:FinnProstate-3 (FinnProstate-III) – cancelled
8:
89:160 mg/month (with or without low-dose
132:FinnProstate-5 (FinnProstate-V) – cancelled
1161:Scientific organisations based in Finland
753:
661:
331:
222:
159:Other studies by the FinnProstate group
118:300 mg/day initially to prevent
7:
858:randomized FinnProstate Study VII".
135:FinnProstate-6 (FinnProstate-VI) –
106:FinnProstate-4 (FinnProstate-IV) –
85:FinnProstate-2 (FinnProstate-II) –
1052:Cancer Group (SPCG) Study No. 5".
994:10.1111/j.1464-410x.1989.tb06016.x
472:10.1111/j.1464-410x.1990.tb14872.x
437:10.1111/j.1464-410x.1989.tb05946.x
401:10.1111/j.1464-410x.1986.tb05461.x
206:Scandinavian Prostate Cancer Group
25:
663:10.1111/j.1464-410X.2007.07361.x
536:10.1046/j.1464-410x.1998.00688.x
196:) for advanced prostate cancer.
172:for advanced prostate cancer. A
47:who have conducted a series of
1:
1030:10.1016/s0090-4295(99)00580-4
1146:Clinical trial organizations
872:10.3109/21681805.2014.901410
836:10.1016/j.eururo.2012.07.040
324:10.1016/j.eururo.2019.07.001
151:androgen deprivation therapy
1177:
1066:10.1080/003655902762467549
800:10.1016/j.juro.2012.01.122
128:metastatic prostate cancer
1110:10.1080/00365590801943274
959:10.3109/00365599409180495
707:10.1080/00365590902836500
571:10.1080/00365590510031228
110:160 mg/month versus
155:advanced prostate cancer
145:advanced prostate cancer
99:advanced prostate cancer
81:advanced prostate cancer
37:FinnProstate Study Group
1151:Evidence-based medicine
915:10.1002/pros.2990180205
496:Ann Chir Gynaecol Suppl
182:polyestradiol phosphate
137:polyestradiol phosphate
108:polyestradiol phosphate
87:polyestradiol phosphate
73:polyestradiol phosphate
41:scientific researchers
1098:Scand J Urol Nephrol
1054:Scand J Urol Nephrol
947:Scand J Urol Nephrol
695:Scand J Urol Nephrol
559:Scand J Urol Nephrol
116:cyproterone acetate
615:10.1002/pros.20547
369:Journal of Urology
51:of treatments for
29:FinnProstate Group
281:Ann Chir Gynaecol
16:(Redirected from
1168:
1130:
1129:
1092:
1086:
1085:
1048:
1042:
1041:
1012:
1006:
1005:
977:
971:
970:
941:
935:
934:
898:
892:
891:
854:
848:
847:
818:
812:
811:
782:
776:
775:
757:
733:
727:
726:
690:
684:
683:
665:
641:
635:
634:
597:
591:
590:
554:
548:
547:
518:
512:
511:
490:
484:
483:
455:
449:
448:
419:
413:
412:
383:
377:
376:
360:
354:
353:
335:
306:
297:
296:
276:
267:
266:
264:
258:, archived from
247:
236:
69:ethinylestradiol
39:, is a group of
21:
1176:
1175:
1171:
1170:
1169:
1167:
1166:
1165:
1156:Prostate cancer
1136:
1135:
1134:
1133:
1094:
1093:
1089:
1050:
1049:
1045:
1014:
1013:
1009:
979:
978:
974:
943:
942:
938:
900:
899:
895:
856:
855:
851:
820:
819:
815:
784:
783:
779:
735:
734:
730:
692:
691:
687:
643:
642:
638:
599:
598:
594:
556:
555:
551:
520:
519:
515:
492:
491:
487:
457:
456:
452:
421:
420:
416:
385:
384:
380:
362:
361:
357:
308:
307:
300:
278:
277:
270:
262:
256:
245:
238:
237:
224:
219:
202:
180:trial assessed
166:
61:
59:Clinical trials
53:prostate cancer
49:clinical trials
23:
22:
15:
12:
11:
5:
1174:
1172:
1164:
1163:
1158:
1153:
1148:
1138:
1137:
1132:
1131:
1087:
1043:
1007:
972:
936:
893:
849:
813:
794:(6): 2074–81.
777:
728:
685:
636:
592:
565:(4): 294–300.
549:
513:
485:
450:
414:
378:
355:
318:(5): 586–595.
298:
268:
254:
221:
220:
218:
215:
214:
213:
208:
201:
198:
165:
164:Related trials
162:
161:
160:
157:
147:
133:
130:
104:
101:
83:
60:
57:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1173:
1162:
1159:
1157:
1154:
1152:
1149:
1147:
1144:
1143:
1141:
1127:
1123:
1119:
1115:
1111:
1107:
1103:
1099:
1091:
1088:
1083:
1079:
1075:
1071:
1067:
1063:
1060:(6): 405–13.
1059:
1055:
1047:
1044:
1039:
1035:
1031:
1027:
1024:(3): 328–33.
1023:
1019:
1011:
1008:
1003:
999:
995:
991:
987:
983:
976:
973:
968:
964:
960:
956:
952:
948:
940:
937:
932:
928:
924:
920:
916:
912:
908:
904:
897:
894:
889:
885:
881:
877:
873:
869:
866:(6): 513–22.
865:
861:
853:
850:
845:
841:
837:
833:
830:(1): 111–20.
829:
825:
817:
814:
809:
805:
801:
797:
793:
789:
781:
778:
773:
769:
765:
761:
756:
751:
748:(3): 175–81.
747:
743:
739:
732:
729:
724:
720:
716:
712:
708:
704:
701:(4): 265–70.
700:
696:
689:
686:
681:
677:
673:
669:
664:
659:
656:(9): 1090–5.
655:
651:
647:
640:
637:
632:
628:
624:
620:
616:
612:
609:(4): 447–55.
608:
604:
596:
593:
588:
584:
580:
576:
572:
568:
564:
560:
553:
550:
545:
541:
537:
533:
529:
525:
517:
514:
509:
505:
501:
497:
489:
486:
481:
477:
473:
469:
465:
461:
454:
451:
446:
442:
438:
434:
430:
426:
418:
415:
410:
406:
402:
398:
395:(5): 528–33.
394:
390:
382:
379:
374:
370:
366:
359:
356:
351:
347:
343:
339:
334:
329:
325:
321:
317:
313:
305:
303:
299:
294:
290:
287:(6): 277–83.
286:
282:
275:
273:
269:
265:on 2021-09-08
261:
257:
251:
244:
243:
235:
233:
231:
229:
227:
223:
216:
212:
209:
207:
204:
203:
199:
197:
195:
191:
187:
183:
179:
175:
171:
163:
158:
156:
152:
148:
146:
142:
138:
134:
131:
129:
125:
121:
117:
113:
109:
105:
102:
100:
96:
92:
88:
84:
82:
78:
74:
70:
66:
65:
64:
58:
56:
54:
50:
46:
42:
38:
34:
30:
19:
1104:(3): 220–9.
1101:
1097:
1090:
1057:
1053:
1046:
1021:
1017:
1010:
988:(3): 290–6.
985:
981:
975:
953:(2): 171–8.
950:
946:
939:
909:(2): 131–7.
906:
902:
896:
863:
860:Scand J Urol
859:
852:
827:
823:
816:
791:
787:
780:
745:
741:
731:
698:
694:
688:
653:
649:
639:
606:
602:
595:
562:
558:
552:
527:
523:
516:
499:
495:
488:
463:
459:
453:
431:(5): 512–4.
428:
424:
417:
392:
388:
381:
372:
368:
358:
333:10138/306830
315:
311:
284:
280:
260:the original
241:
167:
120:gonadotropin
62:
36:
32:
28:
26:
18:Finnprostate
530:(1): 63–8.
466:(1): 94–7.
190:orchiectomy
186:triptorelin
141:orchiectomy
95:orchiectomy
77:orchiectomy
1140:Categories
375:(4): A339.
255:1900640376
217:References
122:flare) in
982:Br J Urol
524:Br J Urol
460:Br J Urol
425:Br J Urol
389:Br J Urol
350:199389424
194:flutamide
170:goserelin
112:buserelin
93:) versus
1126:38638336
1118:18432528
1074:12623503
1038:10699602
931:27915767
903:Prostate
888:24864704
880:24679247
844:22857983
824:Eur Urol
808:22498230
772:38212069
764:10334106
742:Prostate
723:24321902
715:19382005
672:18070186
631:20549248
623:17219379
603:Prostate
587:24752258
579:16261661
522:Group".
342:31375279
312:Eur Urol
200:See also
124:advanced
1082:2799580
1018:Urology
1002:2679960
967:7939468
923:2006119
680:2843818
650:BJU Int
544:9698663
508:8291869
502:: 5–8.
480:2132303
445:2659136
409:3779355
293:4096480
174:British
91:aspirin
45:Finland
1124:
1116:
1080:
1072:
1036:
1000:
965:
929:
921:
886:
878:
842:
806:
788:J Urol
770:
762:
721:
713:
678:
670:
629:
621:
585:
577:
542:
506:
478:
443:
407:
348:
340:
291:
252:
178:SPCG-5
114:(with
35:), or
1122:S2CID
1078:S2CID
927:S2CID
884:S2CID
768:S2CID
719:S2CID
676:S2CID
627:S2CID
583:S2CID
346:S2CID
263:(PDF)
246:(PDF)
192:plus
1114:PMID
1070:PMID
1034:PMID
998:PMID
963:PMID
919:PMID
876:PMID
840:PMID
804:PMID
760:PMID
711:PMID
668:PMID
619:PMID
575:PMID
540:PMID
504:PMID
476:PMID
441:PMID
405:PMID
338:PMID
289:PMID
250:ISBN
153:for
143:for
97:for
79:for
27:The
1106:doi
1062:doi
1026:doi
990:doi
955:doi
911:doi
868:doi
832:doi
796:doi
792:187
750:doi
703:doi
658:doi
654:101
611:doi
567:doi
532:doi
500:206
468:doi
433:doi
397:doi
373:135
328:hdl
320:doi
188:or
126:or
43:in
1142::
1120:.
1112:.
1102:42
1100:.
1076:.
1068:.
1058:36
1056:.
1032:.
1022:55
1020:.
996:.
986:64
984:.
961:.
951:28
949:.
925:.
917:.
907:18
905:.
882:.
874:.
864:48
862:.
838:.
828:63
826:.
802:.
790:.
766:.
758:.
746:39
744:.
740:.
717:.
709:.
699:43
697:.
674:.
666:.
652:.
648:.
625:.
617:.
607:67
605:.
581:.
573:.
563:39
561:.
538:.
528:82
526:.
498:.
474:.
464:66
462:.
439:.
429:63
427:.
403:.
393:58
391:.
371:.
367:.
344:.
336:.
326:.
316:76
314:.
301:^
285:74
283:.
271:^
225:^
33:FP
1128:.
1108::
1084:.
1064::
1040:.
1028::
1004:.
992::
969:.
957::
933:.
913::
890:.
870::
846:.
834::
810:.
798::
774:.
752::
725:.
705::
682:.
660::
633:.
613::
589:.
569::
546:.
534::
510:.
482:.
470::
447:.
435::
411:.
399::
352:.
330::
322::
295:.
31:(
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.